

YYJYYJYYY JYYJYYJYY YYJYYJYY YYJYYJYY

 \mathbf{x}

T

Novartis Finland

The opinions expressed during this presentation represent my own opinions and Novartis should not be kept responsible of them.

Finnish health data landscape – perspectives from pharma industry

Maija Wolf, Nordic RWE Lead Novartis Finland 5th Digital Health Society Summit November 14, 2023

P3-approval number FI2311091837

Novartis invests into Nordic RWE generation Nordic Evidence Generation



- Transforming data into real world evidence to:
- ✔ Optimize development
- Facilitate access to innovative solutions
- Improve medical practices

5250+50+Planned & Completed ongoing RWE studiesPublications



Key Success Factors

Data & biobanked specimens

Infrastructure and processes

Innovative research ecosystems Government priority and citizen's trust









Longitudinal & linkable data and biobanked specimens along with enabling processes



- Social and health sector register data within the scope of the Act on the Secondary Use of Health and Social Data.
- Metadata catalogue

FINBB & FINGENIOUS

- Biospecimens stored in biobanks and associated data in scope of the Biobank Act.
- Fingenious catalogue

4 Business Use Only, P3-approval number FI2311091837





A retrospective register and biobank study of aBC in Finland

Purpose: This retrospective cohort study was designed to describe the distribution of aBC subtypes, incidence, treatment patterns, survival, and PIK3CA hotspot mutation frequency.

Overall goal: To evaluate potential patient numbers for new treatments & to support the reimbursement process of new treatments



Key success factors:

- Access to clinical data through hospital datalakes
- Access to good quality biospecimens through biobanks

Ref: Heinolainen K, et al. Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice. J Cancer Res Clin Oncol. 2023 Sep;149(11):9139-9149. doi: 10.1007/s00432-023-04723-0. Epub 2023 May 13. PMID: 37178424; PMCID: PMC10374819.



Reimagining Medicine



Success Factors for Future & EHDS

- Continue development of the enabling infrastructure
- Secure competitiveness through EHDS and reform of the EU pharmaceutical legislation
- Increase the benefit to individuals and society



YXXYXXXXX YYXYYXYY **YXXXXXXXX** YYXYYXY **YXXYXXXXX** YYYYYYYYY **YXXYXXXXX YXXYXXXXX YXXYXXXXX** YYXYYXYYY **YXXYXXXXX** YYYYYYYYY **YXXYXXXXX** YYXYYXYYY \mathbf{x} **TTTTTTTT** \mathbf{x} YYXYYXYYY **LYXXYXXXX** YYXYYXYYY YXXXXXXXX YYXYYXYYY TAXYXXXXXX TAXXXXXXXXX **YYYYYYYY** YYYYYYYYY **XXXXXXXXXX** YYYYYYYYY **XXXXXXXXXX** YYYYYYYYYY**XXXXXXXXXX** YYXYYXYY YXXYXXXXX YYXYYXYY **YXXYXXXXX** YYXYYXYYY **YXXYXXXXX** YYXYYXYYY **YXXYXXXXX YXXYXXXXX** \mathbf{x} **YXXYXXXXX** YYYYYYYYYY

Thank you

Maija Wolf

maija.wolf@novartis.com